|
|
Expert Insight Into: Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit from an anti-EGFR Monoclonal Antibody in Wild-Type KRAS Metastatic Colon Cancer
Dr. Leonard Saltz discusses the results of a recent retrospective study that examined the ability of various elements of the EGFR signaling pathway to predict outcomes in patients with metastatic colorectal cancer treated with an anti-EGFR monoclonal antibody. He also discusses the results from another study that investigated some of these same elements in patients with advanced colorectal cancer treated with chemotherapy. —
Article Review
|
|
|
|
Expert Insight Into: EGFR Tyrosine Kinase Inhibitor or Combination Chemotherapy in Advanced Pulmonary Adenocarcinoma.
(Part 2 of Series)
The EGFR tyrosine kinase inhibitor gefitinib has demonstrated significant efficacy in patients with previously treated NSCLC. In this course, Dr. Roy Herbst reviews the findings from a randomized phase III trial that compared single-agent gefitinib versus combination chemotherapy with carboplatin and paclitaxel for the initial treatment of advanced pulmonary adenocarcinoma in selected patients in East Asia. —
Article Review
|
|
|
|
Expert Insight Into: A Human Epidermal Growth Factor Receptor 2 (HER2)-Specific Monoclonal Antibody Plus an Aromatase Inhibitor (AI) Versus an AI Alone for the Treatment of Postmenopausal Women with HER2–Positive/Hormone Receptor-Positive Metastatic Breast Cancer.
Dr. Ana Maria Gonzalez-Angulo reports on results of the recently published Phase III TAnDEM study, the first clinical trial in postmenopausal women to combine a hormonal agent and trastuzumab without chemotherapy in the treatment of HER2 and hormone receptor copositive metastatic breast cancer. —
Article Review
|
|
|
|
Expert Insight Into: Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer (Part 1 of Series)
EGFR gene mutations can produce hypersensitivity to EGFR tyrosine kinase inhibitors in patients with NSCLC, but studies investigating the clinical benefit of this approach in these patients have been lacking. Dr. Corey Langer comments on the findings from a prospective, large-scale study of erlotinib in NSCLC patients with EGFR mutations. —
Article Review
|
|
|
|
Expert Insight Into: Physical Activity and Male Colorectal Cancer Survival
Although the protective effects of physical activity on the development of colorectal cancer are well recognized, data on the role of physical activity on outcomes in patients diagnosed with colorectal cancer are limited. In this course, Dr. Cathy Eng reviews the findings of a study that assessed the effects of post-diagnosis leisure-time physical activity on mortality in patients diagnosed with nonmetastatic colorectal cancer. —
Article Review
|
|
|
|
Case Study: Incurable Metastatic Colorectal Cancer
In this newsletter, Dr. Leonard Saltz presents the case of a 57-year-old man with synchronous metastatic rectal cancer to illustrate the decision-making process with regard to management of the primary tumor and choice of systemic therapies for both first- and second-line treatment of metastatic disease. Dr. Saltz also describes all of the available options and reviews the related data from recent clinical trials. —
Tx Reporter e-Newsletter
|
|
|
|
Expert Insight Into: High Risk of Recurrence for Breast Cancer Patients with HER2-Positive, Node-Negative Tumors 1 cm. or Smaller
Studies examining monoclonal antibody therapy against human epidermal growth factor receptor 2 (HER2) have excluded patients with node-negative tumors smaller than 1 cm. Dr. Ana Maria Gonzalez-Angulo and colleagues recently evaluated risk of recurrence in patients with small node-negative HER2-positive tumors. In this course, Dr. Gonzalez-Angulo comments on the findings and their implications for future clinical trials. —
Article Review
|
|
|
|
Expert Insight Into: Preoperative Radiotherapy Versus Selective Postoperative Chemoradiotherapy in Patients with Rectal Cancer (MRC CR07 and NCIC-CTG C016): A Multicentre, Randomised Trial
On average, patients with rectal cancer who experience a local or regional recurrence fare quite poorly and can be expected to live no longer than 18 months. A recent clinical trial compared a short course of preoperative radiotherapy with selective postoperative chemoradiotherapy. Join Dr. Elin R. Sigurdson as she discusses the results, and learn which approach was preferred. —
Article Review
|
|
|
|
Multidisciplinary Hepatocellular Carcinoma Virtual Tumor Board Discussion #2
Join Dr. Mary F. Mulcahy, a medical oncologist, as she leads a multidisciplinary team discussion on the management of advanced hepatocellular carcinoma. With her on the team are Dr. Jean Francois H. Geschwind, an interventional radiologist; Dr. Robert G. Gish, a hepatologist; and Dr. Alan W. Hemming, a surgeon. This course is part of The Advanced Certificate Program in Hepatocellular Carcinoma. —
Podcast Series
|
|
|
|
Multidisciplinary Hepatocellular Carcinoma Virtual Tumor Board Discussion #1
Experience the benefits of a multidisciplinary team in this virtual tumor board. Join Drs. Gary L. Davis, Alan W. Hemming, Mary F. Mulcahy, and Riad Salem as they discuss the management of a patient with hepatitis B-induced locoregional HCC from the perspectives of hepatology, medical oncology, surgery, and interventional radiology. This course is part of The Advanced Certificate Program in Hepatocellular Carcinoma. —
Podcast Series
|
|
|
|
Expert Insight Into: Patterns and Risk Factors Associated with Aromatase Inhibitor-Related Arthralgia Among Breast Cancer Survivors
Aromatase inhibitors (AI) are a standard, and successful, adjuvant therapy for postmenopausal survivors of hormone-receptor positive breast cancer; however, arthralgia is a common side effect. Dr. Harold J. Burstein provides expert commentary on a recent study that measured the patient-reported characteristics of AI-related arthralgia and produced important information about the onset and pattern of arthralgia as it relates to AI therapy. —
Article Review
|
|
|
|
Myeloid Leukemia
The overwhelming majority of patients with chronic myeloid leukemia (CML) can now be successfully treated, and complete remissions can be maintained for many years. Patients with acute myeloid leukemia (AML) are not so fortunate, although complete remission can be achieved in more than half of AML patients. This chapter, edited by Neil Shah, MD, PhD, discusses the rationale for treatment approaches now in use for CML and AML. —
Chapter 3
|
|
|
|
Expert Insight Into:
Microsatellite Instability and Response to Adjuvant Therapy in Patients with Stage III Colon Cancer
Studies have shown that patients with high levels of mismatch repair deficit/high microsatellite instability (MMR-D/MSI-H) experience no benefit from adjuvant chemotherapy that includes fluorouracil (FU). In this course, Dr. Jeffrey Meyerhardt reviews a recent prospective study that sought to determine if patients with MMR-D/MSI-H tumors achieved better overall outcome from, or were more likely to respond to, FU/LV or IFL (irinotecan, 5-FU, and leucovorin). —
Article Review
|
|
|
|
Expert Insight Into: Liver Fibrosis: Consensus Recommendations of the Asian Pacific Association for the Study of the Liver (APASL)
In this review, Dr. W. Ray Kim summarizes the recent recommendations of the Asian Pacific Association for the Study of the Liver (APASL) for the assessment of liver fibrosis in patients with chronic liver disease. The consensus statements include how to properly perform liver biopsies as well as the appropriateness of less invasive alternatives to biopsy.
—
Article Review
|
|
|
|
Case Study: Locally Advanced (T3N0) Rectal Cancer
Dr. Elin Sigurdson presents the case of a 65-year-old man with T3N0 rectal cancer to illustrate appropriate use of imaging technologies for preoperative staging as well as current thinking regarding neoadjuvant and adjuvant therapy. She discusses how surgical approaches have evolved to help improve outcomes while preserving bowel, bladder, and sexual function, and also elaborates on controversies and hypothetical situations that could have changed the management plan for this patient. —
Tx Reporter e-Newsletter
|
|
|
|
Expert Insight Into: Micrometastases or Isolated Tumor Cells and the Outcome of Breast Cancer
Axillary lymph node status is the most important prognostic factor in breast cancer, but its effects on clinical outcome in early-stage disease are not known. In this course, Dr. William Gradishar reviews the findings of a study conducted to determine if a relationship exists between isolate tumor cells or micrometastases in the regional lymph nodes and clinical outcome in patients who did or did not receive systemic adjuvant therapy. —
Article Review
|
|
|
|
Case Study: Adjuvant Therapy in Hormone-Sensitive, HER2-Negative Breast Cancer
Personalized medicine is becoming more of a reality. To illustrate some of the strides being made, Dr. William Gradishar presents the case of a 62-year-old administrative assistant with hormone-positive HER2-negative breast cancer. Through this patient, Dr. Gradishar shows us his decision-making process in selecting the most appropriate adjuvant therapy for her and following up to ensure tolerability and adherence. —
Tx Reporter e-Newsletter
|
|
|
|
Update in Hepatocellular Carcinoma - The Latest Information on Pathogenesis, Screening and Treatment
In this insightful four-part audio podcast, Drs. Gary Davis and Robert Gish discuss several important findings presented at a recent major hepatology conference. Listen and learn as Drs. Davis and Gish review epidemiology/pathogenesis of HCC, serum markers and surveillance, treatment efficacy, and safety of locoregional therapy. —
Podcast Series
|
|
|
|
Expert Insight Into: Outcome of Primary Tumor in Patients with Synchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery as Initial Treatment
For patients with stage IV CRC, the risks and benefits of deferred surgery have not been fully evaluated, but chemotherapy has been shown to improve response and disease control rates, and increase the median survival rate. In this course, Dr. Jeffrey Meyerhardt reviews a recent study that assessed the use of modern triple-drug chemotherapy without prophylactic surgery in a group of patients with asymptomatic, stage IV CRC. —
Article Review
|
|
|
|
Expert Insight Into: Survival Among Women with Triple Receptor-Negative Breast Cancer and Brain Metastases
Survival outcomes and incidence of developing brain metastases have been inferred for patients with nonmetastatic triple receptor-negative breast cancer, but not directly measured. Dr. Ana Maria Gonzalez-Angulo describes a study on the incidence of brain metastases and survival in women originally diagnosed with triple-negative, nonmetastatic breast cancer. —
Article Review
|
|
|
|
Expert Insight Into: Predicting Survival After Liver Transplantation in Patients with Hepatocellular Carcinoma Beyond the Milan Criteria: A Retrospective, Exploratory Analysis
A recent study explored survival following liver transplant in patients with HCC whose tumors exceed the dichotomous—and strict—Milan criteria, using a novel prognostic mathematic model based on objective morphologic and histologic characteristics according to the main parameters used in the tumor node metastasis classification. This course presents the findings of this interesting study and features expert clinical insights from Dr. Robert G. Gish. —
Article Review
|
|
|
|
Expert Insight Into: Influence of Coexisting Cirrhosis on Outcomes After Partial Hepatic Resection for Hepatocellular Carcinoma Fulfilling the Milan Criteria: An Analysis of 293 Patients
Orthotopic liver transplantation is a viable treatment for HCC with comorbid liver cirrhosis in patients who meet the Milan criteria, but there are also potential advantages to performing a liver resection. Dr. Alan W. Hemming provides expert commentary on a recent study that reviewed the clinical outcomes of patients, with and without cirrhosis, who underwent hepatic resection for the treatment of HCC. —
Article Review
|
|
|
|
Overview of Leukemia
Understanding of the molecular biology underpinnings of the leukemias is growing by leaps and bounds and has given rise to new therapies. In this introductory chapter, Dr. Jerald Radich highlights what is known about the relationship between the genetic changes that distinguish the different types of leukemias and the clinical implications of these changes. —
Chapter 1
|
|
|
|
Personalizing Breast Cancer Management: Update on Targeted Therapies and Molecular Diagnostics
Listen as Drs. Harold J. Burstein and Ian E. Smith provide an update on targeted therapies and how to personalize their use in the treatment of breast cancer. The discussion focuses on how to optimize trastuzumab regimens, treatment of small HER2-positive lesions, other HER2 agents, PARP inhibitors, and antiangiogenesis inhibitors. Drs. Burstein and Smith also address the use of molecular diagnostic tools to identify patients likely to benefit from adjuvant chemotherapy. —
Audio Interview Series
|
|
|
|
Expert Insight Into: Efficacy of Drug-Eluting Beads in Chemoembolization of Hepatocellular Carcinoma
The addition of drug-eluting beads loaded with chemotherapy to transarterial chemoembolization (TACE) is a safe and effective treatment option for intermediate and advanced HCC, allowing the ability to selectively inject higher doses of chemotherapy to target tumors compared with conventional TACE. This course reports on the findings of this recent phase II clinical study and features expert commentary by Dr. Riad Salem. —
Article Review
|
|
|
|
Expert Insight Into: Patients with Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?
Most patients with colorectal liver metastases have unresectable disease at diagnosis. Although chemotherapy can prolong patient survival, it remains inferior to resection. Methods to convert unresectable to resectable metastases have been successful in some patients, enhancing long-term survival, but the potential for cure is uncertain. A recent trial assessed cure, defined as 5-year disease-free survival, in patients with unresectable liver metastases responsive to downsizing chemotherapy. Dr. Sigurdson discusses the results of this trial and the prognostic factors associated with cure. —
Article Review
|
|
|
|
Case Study: Stage IV Colon Cancer with Potential for Conversion to Resectability
In this illustrative case study of a 58-year-old man with liver-only metastases, Dr. Jeffrey Meyerhardt describes current recommendations with regard to candidacy for surgical resection, various strategies for converting initially unresectable colorectal liver metastases to resectability, and appropriate selection of neoadjuvant and adjuvant therapies to maximize response and survival outcomes. —
Tx Reporter e-Newsletter
|
|
|
|
Expert Insight Into: Sustained Virological Response to Interferon-α Is Associated with Improved Outcome in HCV-related Cirrhosis: A Retrospective Study
This retrospective, multicenter study suggests that the achievement of sustained virological response following interferon treatment in patients with hepatitis C virus–related cirrhosis is associated with a decrease in liver-related mortality, a lower risk of liver-related complications, and a lower risk of developing hepatocellular carcinoma. Dr. Gary L. Davis comments on these findings. —
Article Review
|
|
|
|
Expert Insight Into: Antitumor Activity of PARP Inhibitors in Tumors with BRCA Mutations
In this article review, Dr. Maura Dickler discusses the pharmacokinetics, pharmacodynamics, safety, and antitumor activity of olaparib in patients with advanced solid tumors refractory to the standard of care, including patients with and without confirmed BRCA1 or BRCA2 mutations, reported from a phase I trial. —
Article Review
|
|
|
|
Expert Insight Into: Treatment of Hepatocellular Carcinoma with a Small Molecule Multi-Tyrosine Kinase Inhibitor
Hepatocellular carcinoma (HCC) poses a major health problem, its incidence is on the rise, and an effective treatment does not presently exist. Dr. Mary F. Mulcahy examines the findings from a recent phase III study that investigated the efficacy and safety of sorafenib in patients with advanced HCC. —
Article Review
|
|
|
|
Expert Insight Into: Perioperative Chemotherapy and Surgery Versus Surgery Alone for Resectable Liver Metastases in Patients with Colorectal Cancer
Survival in colorectal cancer patients with liver metastases is low and the majority of patients relapse following surgical resection. In this article review, Dr. Elin R. Sigurdson discusses results of a clinical trial comparing combined pre- and postoperative FOLFOX4 versus surgery alone and the benefits of this perioperative chemotherapy regimen in increasing progression-free survival in colorectal cancer patients with resectable liver metastases. —
Article Review
|
|
|
|
Case Study: Triple-Negative Breast Cancer
In this Tx Reporter, Maura N. Dickler, MD, presents the case of a 51-year-old African-American woman diagnosed with triple-negative breast cancer. Through this case study, Dr. Dickler discusses the characteristics of triple-negative breast cancer and its implications regarding both prognosis and treatment selection. Dr. Dickler reviews the latest data and treatment recommendations with regard to choice of adjuvant therapy as well as first- and second-line therapy for recurrent/metastatic disease in this high-risk subgroup of breast cancer patients. —
Tx Reporter e-Newsletter
|
|
|
|
Expert Insight Into: Induction Chemotherapy Followed By Concurrent Chemotherapy And Dose-Escalated Thoracic Conformal Radiotherapy In Stage III NSCLC
The use of 3-D planning techniques, which can more accurately target a tumor while reducing exposure of healthy tissue, has enabled safe use of increased doses of thoracic radiotherapy together with induction chemotherapy. A recent trial compared the safety of two chemoradiation regimens as first-line treatment in patients with stage IIIA/B NSCLC. Dr. Elizabeth Gore discusses the findings and their possible impact on patient treatment. —
Article Review
|
|
|
|
Expert Insight Into: Dangers of Chemotherapy Plus Concurrent Anti-EGFR and Anti-VEGF Antibodies in Metastatic Colorectal Cancer
Previous trials have shown that the addition of anti-VEGF or anti-EGFR monoclonal antibody to combined chemotherapy regimens improved overall survival when used as first-line treatment in patients with metastatic colorectal cancer. A recent clinical trial tested whether the combination of both types of antibodies with chemotherapy would further enhance survival. Dr. Saltz discusses the results of this trial and their implication for the treatment of patients with metastatic colorectal cancer. —
Article Review
|
|
|
|
Zeroing in on Non-Small Cell Lung Cancer: Integrating Targeted Therapies into Practice
In this free CME/CE on-demand webcast, a panel of experts in the use of targeted therapies to treat patients with NSCLC will provide up-to-date information on optimizing the use of targeted agents, discussing genomic predictors and their application in determining therapy with targeted agents, current and emerging targeted therapies, and multimodality radiotherapy/targeted therapy.
—
Webcast
|
|
|
|
Expert Insight Into: Hepatocellular Carcinoma Incidence, Mortality, and Survival Trends in the United States from 1975 to 2005
HCC incidence and mortality rates in the United States have risen dramatically over the past 30 years, with differential effects as a factor of race/ethnicity and age-cohort. Concurrently, short-, intermediate-, and longer-term survival have increased, primarily because an increasing percentage of patients are being diagnosed at earlier stages of disease. Dr. Davis discusses these recent epidemiologic trends and the application of this information to the diagnosis and treatment of individuals with HCC. —
Article Review
|
|
|
|
Case Study: NSCLC (Squamous Cell Carcinoma) in a Patient with COPD
Join Drs. Michael Unger and Elizabeth Gore as they weigh options for primary treatment and treatment of local recurrence in a smoker with severe chronic obstructive pulmonary disease (COPD) and early-stage lung cancer. Through this case, they review current guidelines and recent data on lobectomy, various forms of radiation therapy, as well as photodynamic therapy in medically inoperable patients and those with local recurrence. —
Tx Reporter with Audio
|
|
|
|
Expert Insight Into: Association Between Polymorphisms in the VEGF and VEGFR-2 Genes and the Efficacy and Safety of Anti-VEGF Monoclonal Antibody in Patients with Advanced Breast Cancer
In this review of findings from a recent phase III clinical trial, Dr. Maura N. Dickler discusses the results of an analysis of the relationship between genetic variations in VEGF and VEGFR-2 and bevacizumab efficacy and the implication of using biomarkers to target therapy to individual patients with advanced/metastatic breast cancer. —
Article Review
|
|
|
|
Case Study: Postoperative Management of High-Risk Stage II Colon Cancer
Framed around the case of a 42-year-old woman with stage II colon cancer, Dr. Cathy Eng describes how to ensure accurate staging and evaluates current recommendations regarding selection of candidates for adjuvant therapy. She also reviews available data to guide choice of an adjuvant therapy regimen, discusses the management of oxaliplatin-induced neuropathy, and provides current recommendations for ongoing surveillance. —
Tx Reporter e-Newsletter
|
|
|
|
Expert Insight Into: Anti-VEGF plus Oxaliplatin-Based Chemotherapy as First-Line Treatment for Metastatic Colorectal Cancer: A Randomized Phase III Study
Dr. Cathy Eng reports on a recent phase III study that compared the efficacy and safety of bevacizumab plus oxaliplatin-based chemotherapy regimens (capecitabine plus oxaliplatin or fluorouracil/folinic acid plus oxaliplatin) versus the oxaliplatin-based chemotherapy regimens alone as first-line treatment in 1401 patients with metastatic colorectal cancer. —
Article Review
|
|
|
|
Expert Insight Into: Whether to Continue HER2-Targeting Therapy After Disease Progression in Advanced Breast Cancer
Dr. Maura Dickler discusses findings from a phase III trial that investigated whether patients with HER2-positive advanced breast cancer who were treated with trastuzumab after disease progression and second-line chemotherapy experienced a longer time to progression than those treated with chemotherapy alone. —
Article Review
|
|
|
|
Expert Insight Into: Postoperative Radiation Therapy in Patients with Complete Resection and Stage I, II, or IIIA NSCLC Treated with Adjuvant Chemotherapy
Previous trial results concerning the value of PORT in patients with completely resected NSCLC have been unclear or contradictory. In this course, Dr. Elizabeth Gore discusses the results of a new study that provides support for the use of PORT in patients with pN2 NSCLC and perhaps in some patients with pN1 disease. This article review is part of the Advanced Certificate Program: Lung Cancer Management II. —
Article Review
|
|
|
|
Expert Insight Into: Adjuvant Chemotherapy in Older Women with Early-Stage Breast Cancer
Dr. William Gradishar discusses a recent trial that compared the use of standard adjuvant chemotherapy with adjuvant capecitabine, an oral agent that has shown similar efficacy to standard chemotherapy, in early-stage breast cancer patients aged 65 years or older and comments on the implications of the study results for the treatment of older patients. —
Article Review
|
|
|
|
Expert Insight Into: Endocrine Therapy plus a Bisphosphonate
in Premenopausal Breast Cancer
A recent study evaluated the addition of zoledronic acid to standard treatment with goserelin plus tamoxifen or goserelin plus anastrozole, and also compared goserelin plus an aromatase inhibitor versus standard care (goserelin plus tamoxifen), in premenopausal women with endocrine-responsive early breast cancer. Dr. Harold Burstein discusses the efficacy and safety of these treatment regimens for this patient population. —
Article Review
|
|
|
|
Expert Insight Into: A New Chemotherapy + Targeted Agent Regimen as Initial Treatment for Metastatic Colorectal Cancer
The combination of the angiogenesis inhibitor, bevacizumab, and either FOLFOX or FOLFIRI is a standard first-line therapy for metastatic colorectal cancer (mCRC). Preliminary trials have suggested that the addition of the EGFR inhibitor, cetuximab, may also increase the benefit of treatment with FOLFIRI in patients with metastatic disease. Dr. Meyerhardt discusses results of the recent phase III CRYSTAL trial comparing FOLFIRI vs FOLFIRI+cetuximab as first-line therapy for mCRC and comments on the need to balance efficacy and cetuximab-related toxicities of this combination regimen in determining treatment of newly diagnosed patients. This article review is part of the Certificate Program in Advanced/Metastatic Colorectal Cancer. —
Article Review
|
|
|
|
Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board
Roy S. Herbst, MD, PhD, leads a renowned multidisciplinary faculty of experts in medical oncology, thoracic surgery, pulmonology, and radiation oncology in a virtual tumor board that reviews the case of a 55-year-old man with stage III, N2 NSCLC to illustrate the multitude of options available for staging and treatment. —
Webcast
|
|
|
|
Overview of Osteoporosis
After reviewing the epidemiology of osteoporosis and its associated disease burden, Dr. E. Michael Lewiecki summarizes the physiology of bone remodeling to lay a foundation for understanding the role of current and emerging therapies. In this six-part web-based reference tool, noted experts present up-to-date information about this serious—and growing—health concern. This is part of the Osteoporosis Compendium. —
Chapter 1
|
|
|
|
Expert Insight Into: Relationship Between K-ras Mutation Status and Benefit of Anti-EGFR Antibodies in Advanced Colorectal Cancer
The results from this clinical study add to the growing body of data that indicate that K-ras mutation status in the tumor can be used as a determinant for which patients with advanced colorectal cancer are, and more importantly, are not candidates for anti-EGFR treatment. This article review is part of the Certificate Program in Advanced/Metastatic Colorectal Cancer. —
Article Review
|
|
|
|
Expert Insight Into: Randomized Phase II Trial of Erlotinib or Standard Chemotherapy in Patients with Advanced Non–Small-Cell Lung Cancer and a Performance Status of 2
Dr. Corey Langer discusses results from a phase II trial in this patient population comparing the epidermal growth factor receptor inhibitor erlotinib with combination chemotherapy of paclitaxel plus carboplatin, and comments on the study’s implications for patient management. This article review is part of the Advanced Certificate Program: Lung Cancer Management II. —
Article Review
|
|
|
|
Personalizing the Treatment of Lung Cancer - Managing the Side Effects of Targeted Therapies
The development of targeted therapies to treat solid tumors, including lung cancer, has revolutionized cancer treatment and management, changing from the “one-size-fits-all” model to a more customized approach. With new advances and data emerging at such a rapid rate, it is critical that nurses stay informed about these exciting new and emerging treatment options—understanding their mechanisms of action, recognizing the unique side effects of these agents, and managing these adverse effects to minimize their impact on patients’ quality of life, morbidity, and mortality.
This free CE satellite symposium, presented by a noted faculty of oncology experts, will provide up-to-date information on the use of targeted therapies, and proper management of associated side effects, in patients with lung cancer. In addition, case-study discussions elaborating on a multidisciplinary approach to the treatment of lung cancer and management of the side effects of treatment will demonstrate practical application in real patient scenarios. —
Satellite Symposium
|
|
|
|
Expert Insight Into: Consolidation Therapy (Docetaxel) Stage III NSCLC
This course reviews a phase III randomized trial that explored the use of docetaxel consolidation following chemoradiation, and its effect on overall survival, in patients with stage III NSCLC. Dr. Corey Langer comments on the findings and potential new treatment strategies for these patients. This article review is part of the Advanced Certificate Program: Lung Cancer Management II. —
Article Review
|
|
|
|
Expert Insight Into: Thoracoscopic Lobectomy Facilitates the Delivery of Chemotherapy After Resection for Lung Cancer
Dr. Joseph Shrager comments on the results of a recent study that compared compliance with adjuvant chemotherapy regimens in groups of patients with non–small-cell lung cancer who underwent thoracoscopic lobectomy or conventional lobectomy by thoracotomy. This article review is part of the Advanced Certificate Program: Lung Cancer Management II. —
Article Review
|
|
|
|
Case Study: Small-Cell Lung Cancer
Utilizing recent clinical study results and current clinical practice guidelines from the National Comprehensive Cancer Network, Dr. Elizabeth M. Gore reviews options for the initial treatment of a 60-year-old patient who presents with limited-stage small-cell lung cancer (SCLC). This course is a part of the Advanced Certificate Program: Lung Cancer Management II. —
Tx Reporter e-Newsletter
|
|
|
|
Practice Tools to Manage Patients with Chronic Phase CML
—
Practice Tool
|
|
|
|
Clinician's Digest
Easy-to-reference clinical tool, designed to reinforce the information found in the Side Effects Handbook, part of the ongoing online CME/CE curriculum Caring for Oncology Patients: Tips and Tools for Managing Targeted Therapy. —
Clinician's Digest
|
|
|
|
Expert Insight Into: Irinotecan Plus Carboplatin Versus Oral Etoposide Plus Carboplatin In Extensive Small-Cell Lung Cancer: A Randomized Phase III Trial
Dr. Ramaswamy Govindan comments on the results of a phase III clinical trial from Norway and Sweden that compared a regimen consisting of intravenous irinotecan plus carboplatin with a regimen consisting of oral etoposide plus intravenous carboplatin in patients with extensive SCLC. This article review is part of the Advanced Certificate Program: Lung Cancer Management II.
—
Article Review
|
|
|
|
Case Study: Limited Multifocal Bronchioloalveolar Adenocarcinoma (BAC)
Dr. Joseph B. Shrager presents the case of a 61-year-old woman with limited multifocal BAC, reviews the latest research documenting appropriate surgical treatment strategies for such patients, and considers the efficacy and safety of targeted agents that may be administered post-surgery. —
Tx Reporter e-Newsletter
|
|
